v3.26.1
Identifiable Intangible Assets, Net and Goodwill
 3 Months Ended
Mar. 29, 2026
Goodwill and Intangible Assets Disclosure [Abstract]  
Identifiable Intangible Assets, Net and Goodwill Identifiable Intangible Assets, Net and Goodwill
A. Identifiable Intangible Assets
The following summarizes the components of Identifiable intangible assets:
March 29, 2026December 31, 2025
(MILLIONS)Gross
Carrying
Amount		Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Gross
Carrying
Amount		Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Finite-lived intangible assets
Developed technology rights(a)
$101,396 $(71,491)$29,905 $100,630 $(70,172)$30,458 
Brands1,035 (1,035)— 1,035 (1,035)— 
Licensing agreements and other2,350 (1,336)1,013 2,341 (1,289)1,052 
104,780 (73,862)30,918 104,006 (72,496)31,510 
Indefinite-lived intangible assets
IPR&D(a)
21,180 21,180 21,760 21,760 
Licensing agreements and other
460 460 460 460 
21,641 21,641 22,221 22,221 
Identifiable intangible assets
$126,421 $(73,862)$52,559 $126,227 $(72,496)$53,731 
(a)The gross carrying amounts reflect a transfer of $580 million from IPR&D to developed technology rights for Tukysa (tucatinib).
B. Goodwill
As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the first quarter of 2026 (see Note 13A), our goodwill is required to be reallocated amongst impacted reporting units. The reallocation of goodwill is a complex process that requires, among other things, determination of the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. The reallocation will be completed in the current fiscal year. All goodwill continues to be assigned within the Biopharma reportable segment.